Provided by Tiger Fintech (Singapore) Pte. Ltd.

Compass Therapeutics, Inc.

1.94
-0.1800-8.49%
Post-market: 1.92-0.0200-1.03%19:41 EDT
Volume:878.09K
Turnover:1.73M
Market Cap:268.27M
PE:-5.40
High:2.15
Open:2.11
Low:1.91
Close:2.12
Loading ...

Compass Therapeutics Price Target Maintained With a $24.00/Share by HC Wainwright & Co.

Dow Jones
·
22 Apr

Compass Therapeutics’ Tovecimig Shows Promise in BTC Treatment, Supporting Buy Rating

TIPRANKS
·
21 Apr

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients With Biliary Tract Cancer

THOMSON REUTERS
·
21 Apr

Compass Therapeutics Inc. - Secondary Endpoint Results Expected in Q4

THOMSON REUTERS
·
21 Apr

Major Stock Sell-Off at Compass Therapeutics by Key Directors!

TIPRANKS
·
12 Apr

Insider Moves: Key Executives Snap Up Compass Therapeutics Stock

TIPRANKS
·
09 Apr

Compass Therapeutics Price Target Maintained With a $12.00/Share by Guggenheim

Dow Jones
·
02 Apr

Compass Therapeutics Raised to Outperform From Market Perform by Leerink Partners

Dow Jones
·
02 Apr

Compass Therapeutics (CMPX) Receives a Buy from Guggenheim

TIPRANKS
·
02 Apr

Compass Therapeutics And 2 More Compelling Penny Stocks

Simply Wall St.
·
02 Apr

Leerink Partners Upgrades Compass Therapeutics to Outperform From Market Perform, Adjusts PT to $6 From $4

MT Newswires Live
·
02 Apr

Compass Therapeutics upgraded to Outperform from Market Perform at Leerink

TIPRANKS
·
02 Apr

Positive Buy Rating for Tovecimig-Paclitaxel Combo Following Promising COMPANION-002 Trial Results

TIPRANKS
·
02 Apr

Compass Therapeutics Inc. : Leerink Partners Raises to Outperform From Market Perform; Raises Target Price to $6 From $4

THOMSON REUTERS
·
02 Apr

BUZZ-Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms

Reuters
·
01 Apr

Compass Therapeutics Says its Ongoing Biliary Tract Cancer Combination Drug Trial Indicates Statistically Significant Overall Response Rate

MT Newswires Live
·
01 Apr

Tovecimig (Ctx-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients With Biliary Tract Cancer

THOMSON REUTERS
·
01 Apr

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

GlobeNewswire
·
01 Apr

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

GlobeNewswire
·
01 Apr

Compass Therapeutics, Inc.'s (NASDAQ:CMPX) market cap decline of US$44m may not have as much of an impact on institutional owners after a year of 0.5% returns

Simply Wall St.
·
30 Mar